SecBot SecBot
Biotech Drug Report Generated Oct 30, 2026

brezosiran

ALNY·ALNYLAM PHARMACEUTICALS, INC.
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 1b
Time to market
If the pivotal study begins in 2027 as planned, a potential approval would be several years away, likely 2029-2031 assuming positive Phase 3 data and a standard FDA review timeline.
Why 3/10
Brezosiran is a Phase 1b asset with no hard dated binary catalyst in the next ~12 months; the next step is a pivotal study planned for 2027 (no specific date), and Alnylam is a large, diversified company with multiple approved products, so brezosiran represents a small fraction of overall value.
Actionable Insight NEUTRAL

The next catalyst for brezosiran is the planned initiation of a placebo-controlled pivotal study in 2027, pending regulatory alignment. Positive Phase 1b data (60-64% mean mHTT reduction) supports advancement, but the drug is still early-stage and represents a small part of Alnylam's diversified, approved-product portfolio. Watch for regulatory feedback and trial design details in 2027.

Price Chart

Loading chart...

Executive Summary

Brezosiran (ALN-HTT02) is Alnylam Pharmaceuticals' investigational RNAi therapeutic for Huntington's disease, administered intrathecally using the C16 conjugate platform for CNS delivery. On October 23, 2026, Alnylam reported positive initial Phase 1b data showing mean CSF mutant huntingtin reductions of 60-64% at month 3 (highest dose) with individual reductions up to 83%, and an encouraging safety profile supporting potential twice-yearly dosing. The company plans to initiate a placebo-controlled pivotal study in 2027, pending regulatory alignment. Brezosiran is early-stage (Phase 1b) and represents a small portion of Alnylam's value; the company is a large, diversified RNAi leader with multiple approved products (Amvuttra, Onpattro) that drove $1.3B in Q3 2026 product revenues. ALNY stock fell ~25% on October 29, 2026 due to commercial headwinds for Amvuttra, unrelated to brezosiran.

How It Works

Brezosiran is an RNA interference (RNAi) therapy that uses a short piece of genetic material to 'silence' the huntingtin gene, reducing production of the toxic huntingtin protein that causes Huntington's disease. It is injected into the spinal fluid (intrathecal) to reach the brain, and uses Alnylam's C16 conjugate technology to help the drug enter cells in the central nervous system. It targets exon 1 of the HTT gene, reducing both the full-length mutant huntingtin protein and a shorter toxic fragment called HTT1a.

Trial Status

An ongoing randomized, double-blind, placebo-controlled Phase 1b single ascending dose study in adults with Huntington's disease (HD-ISS Stage 2 or early Stage 3) presented interim data at EHDN October 2026. Initial results showed dose-dependent mHTT reductions with encouraging safety. Alnylam plans to initiate a placebo-controlled pivotal study in 2027 pending regulatory alignment.

The Two-Sided Case

▲ Bull Case5
Phase 1b data showed best-in-class huntingtin knockdown: mean 60-64% reduction of CSF mutant huntingtin at month 3 in the highest dose group, with individual reductions up to 83%, surpassing competitors like WVE-003 (46%).
Encouraging safety and tolerability profile with potential for convenient twice-yearly dosing via intrathecal administration, which could enhance patient adherence.
Alnylam plans a placebo-controlled pivotal study in 2027, which would be the first placebo-controlled test of the huntingtin 1a-lowering hypothesis, a potentially landmark trial.
Roche's tominersen failure and uniQure's mixed data have left the Huntington's disease field open for a new entrant; brezosiran's unique RNAi mechanism targeting both full-length HTT and HTT1a may differentiate it.
Alnylam is the established leader in RNAi therapeutics with deep expertise, a proven C16 conjugate platform for CNS delivery, and strong financial resources to fund development.
▼ Bear Case5
Phase 1b data do not establish clinical efficacy; the drug has not yet shown it can slow Huntington's disease progression, only that it lowers a biomarker (mHTT protein).
Brezosiran is non-selective, lowering both normal and mutant huntingtin protein, which carries theoretical safety risk since normal huntingtin has important biological functions.
The competitive landscape includes Wave Life Sciences' WVE-003 (allele-selective ASO with 46% mHTT reduction and FDA alignment for accelerated approval), and Roche's tominersen failure highlights how difficult it is to translate biomarker knockdown into clinical benefit in Huntington's.
Alnylam's stock dropped ~25% on October 29, 2026 due to commercial headwinds for its approved drug Amvuttra, unrelated to brezosiran, but the selloff reflects broader company risk.
Brezosiran is an early-stage (Phase 1b) asset at a large, diversified company; even if successful, it represents a small fraction of Alnylam's overall valuation.

Upcoming Catalysts

  • Initiation of placebo-controlled pivotal study in 2027 (date TBD, pending regulatory alignment)
  • Regulatory feedback from FDA/EMA on pivotal trial design

Source Filing

The SecBot filing or press-release report that triggered this drug report:

ALNYLAM PHARMACEUTICALS, INC. 8-K ALNY ·Originating report

Sources · 10

Hover a chip for the title
1 investors.alnylam.com2 hdsa.org3 en.hdbuzz.net4 capella.alnylam.com5 biospace.com6 simianx.ai7 statnews.com8 pomegra.io9 ainvest.com10 pienomial.com